Alnylam Pharmaceuticals Hits New 52-Week Low at $266.43

Alnylam Pharmaceuticals, Inc. has reached a significant milestone by touching a new 52-week low of USD 266.43 on July 17, 2026. This marks a notable decline in the stock's performance, especially when considering its previous high of USD 495.31 within the same period. Despite this recent downturn, Alnylam Pharmaceuticals has demonstrated a robust one-year performance of 74.28%, significantly outperforming the S&P 500, which recorded a gain of 18.43%. The company's market capitalization stands at USD 42,089 million, categorizing it as a mid-cap entity within the Pharmaceuticals and Biotechnology industry. Financial metrics reveal a price-to-earnings (P/E) ratio of 118.00, indicating a premium valuation relative to earnings. Additionally, the company maintains a return on equity of 45.14%, showcasing effective management of shareholder equity. However, it is noteworthy that Alnylam Pharmaceuticals does not offer a dividend yield, and its debt-to-equity ratio is reported at -0.21, reflecting a unique financial structure. As the stock navigates these fluctuations, its performance metrics continue to highlight its position in the market.